Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Dr. Barbara Schmidtman shares valuable strategies for leading effective meetings in a virtual setting.
Developing a Health Literacy and Clear Communications e-Course 2 ASSOCIATION OF COMMUNITY CANCER CENTERS accc-cancer.org AMCCBS Workshop Wednesday, March 8, 2023 2:30pm - 5:30pm S E S S I O N O N E 2:30pm - 2:40pm Welcome and Pre-Assessment 2:40pm - 3:05pm Updates in the Multidisciplinary Management of Breast Cancer Dr. Natalie Rizk, MD, Breast Surgical Oncology …
New Molecular Entities JaypircaTM (pirtobrutinib) – Loxo/Lilly Oncology received approval for its novel BTK inhibitor as treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy (including treatment with another BTK inhibitor). The approval was based on response rates observed among 120 MCL patients who were treated with …
New Molecular Entities JaypircaTM (pirtobrutinib) – Loxo/Lilly Oncology received approval for its novel BTK inhibitor as treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy (including treatment with another BTK inhibitor). The approval was based on response rates observed among 120 MCL patients who were treated with …
February 21, 2023
ACCC has invited providers across the U.S. to discuss the unique challenges seen in their respective regions and address how the current state of cancer care for patients with chronic lymphocytic leukemia (CLL) may be improved.
New Molecular Entities JaypircaTM (pirtobrutinib) – Loxo/Lilly Oncology received approval for its novel BTK inhibitor as treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy (including treatment with another BTK inhibitor). The approval was based on response rates observed among 120 MCL patients who were treated with …
New Molecular Entities JaypircaTM (pirtobrutinib) – Loxo/Lilly Oncology received approval for its novel BTK inhibitor as treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy (including treatment with another BTK inhibitor). The approval was based on response rates observed among 120 MCL patients who were treated with …
New Molecular Entities JaypircaTM (pirtobrutinib) – Loxo/Lilly Oncology received approval for its novel BTK inhibitor as treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy (including treatment with another BTK inhibitor). The approval was based on response rates observed among 120 MCL patients who were treated with …
PowerPoint Presentation Updates from Capitol Hill: What to look for in 2023 Jennifer Brunelle Chief Advocacy Officer February 17, 2023 Disclosure of Conflicts of Interest Jennifer Brunelle has no relevant financial relationships to disclose. ASCO and State Affiliates: Partners in Advocacy • Sign-on letters to Congress • Meetings with federal & state …
PowerPoint Presentation Community Oncology Alliance © www.CommunityOncology.org NCOA/SCOS 2023 Joint Conference Update from Capitol Hill: What to look for in 2023 Ted Okon Executive Director February 17, 2023 Community Oncology Alliance © www.CommunityOncology.org • Ted Okon, MBA, has no relevant financial relationships to disclose. 1 Disclosure of Conflicts …
Today is National Caregivers Day, and ACCCBuzz analyzes the current mental health crisis that is affecting the caregivers of loved ones everywhere.
February 17, 2023
The Association of Community Cancer Centers (ACCC) and the American Society of Clinical Oncology (ASCO) invite you to join a virtual discussion about new resources to help diversify participation in cancer clinical trials.
OUR MISSION: Oncology State Societies at ACCC Engage & Succeed. KANSAS SOCIETY OF CLINICAL ONCOLOGY 1801 Research Blvd, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.kasco-kansas.com APPLICATION FOR MEMBERSHIP Annual membership dues (January 1–December 31) must accompany application. Mail payment with this form …
Updated 11/9/23
OUR MISSION: WYOMING STATE ONCOLOGY SOCIETY 1801 Research Boulevard, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.wsos-wyoming.com Oncology State Societies at ACCC Engage & Succeed. APPLICATION FOR MEMBERSHIP Annual membership dues (January 1–December 31) must accompany application. Mail payment with this form to: Wyoming State Oncology …
OUR MISSION: Oncology State Societies at ACCC Engage & Succeed. NORTH CAROLINA ONCOLOGY ASSOCIATION 1801 Research Blvd, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.ncoa-northcarolina.com APPLICATION FOR MEMBERSHIP Annual membership dues (January 1–December 31) must accompany application. Mail payment with this …
OUR MISSION: Oncology State Societies at ACCC Engage & Succeed. VIRGINIA ASSOCIATION OF HEMATOLOGISTS & ONCOLOGISTS 1801 Research Blvd, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.vah-o.com APPLICATION FOR MEMBERSHIP Annual membership dues (January 1–December 31) must accompany application. Mail payment …
OUR MISSION: ROCKY MOUNTAIN ONCOLOGY SOCIETY 1801 Research Boulevard, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.rmos-colorado.com Oncology State Societies at ACCC Engage & Succeed. APPLICATION FOR MEMBERSHIP Annual membership dues (January 1–December 31) must accompany application. Mail payment with this form to: Rocky Mountain Oncology …
OUR MISSION: Oncology State Societies at ACCC Engage & Succeed. TENNESSEE ONCOLOGY PRACTICE SOCIETY 1801 Research Blvd, Suite 400, Rockville, Maryland 20850 Phone: 301.984.9496 www.tops-tennessee.com APPLICATION FOR MEMBERSHIP Annual membership dues (January 1–December 31) must accompany application. Mail payment with this form …